Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of RES-010 in healthy, overweight, and moderately obese adults
NL-OMON60903Phase 1Completed
- Sponsor
- Resalis Therapeutics
- Start
- Oct 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing RES-010 with Placebo (2 arms). Started Oct 2024; status: completed.
02
Drugs
RES-010
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON60903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60903.